Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II

This publication has 11 references indexed in Scilit:

• Safety of rosuvastatin
  The American Journal of Cardiology, 2004
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
  Circulation, 2004
• Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study
  American Heart Journal, 2004
• Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR * Trial)
  Published by Elsevier ,2003
• Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease
  The American Journal of Cardiology, 2003
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report
  Circulation, 2002
• Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
  American Heart Journal, 2002
• Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy
  Circulation, 2002
• The Lipid Treatment Assessment Project (L-TAP)
  Archives of internal medicine (1960), 2000
• Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease
  The American Journal of Cardiology, 1999